A citation-based method for searching scientific literature

John B Buse, Richard M Bergenstal, Leonard C Glass, Cory R Heilmann, Michelle S Lewis, Anita Y M Kwan, Byron J Hoogwerf, Julio Rosenstock. Ann Intern Med 2011
Times Cited: 389



Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis, Aldo P Maggioni, John J V McMurray, Jeffrey L Probstfield, Matthew C Riddle, Scott D Solomon, Jean-Claude Tardif. N Engl J Med 2015
Times Cited: 1185




List of shared articles



Times cited

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Michael A Nauck, Daniel R Quast, Jakob Wefers, Juris J Meier. Mol Metab 2021
34

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.
Alan J Garber, Yehuda Handelsman, George Grunberger, Daniel Einhorn, Martin J Abrahamson, Joshua I Barzilay, Lawrence Blonde, Michael A Bush, Ralph A DeFronzo, Jeffrey R Garber,[...]. Endocr Pract 2020
126

Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors.
Alexandros Sachinidis, Dragana Nikolic, Anca Pantea Stoian, Nikolaos Papanas, Omer Tarar, Ali A Rizvi, Manfredi Rizzo. Metabolism 2020
14

Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update.
Lorraine Lipscombe, Sonia Butalia, Kaberi Dasgupta, Dean T Eurich, Lori MacCallum, Baiju R Shah, Scot Simpson, Peter A Senior. Can J Diabetes 2020
19

Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Raffaella Gentilella, Valeria Pechtner, Antonella Corcos, Agostino Consoli. Diabetes Metab Res Rev 2019
80

A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes.
Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta, Jesús Reviriego. Diabetes Ther 2019
24

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.
Alan J Garber, Martin J Abrahamson, Joshua I Barzilay, Lawrence Blonde, Zachary T Bloomgarden, Michael A Bush, Samuel Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Vivian A Fonseca,[...]. Endocr Pract 2019
161

Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies.
Guillermo E Umpierrez, Timothy S Bailey, Danielle Carcia, Charles Shaefer, Jay H Shubrook, Neil Skolnik. J Diabetes 2018
8


Pharmacotherapy of type 2 diabetes: An update.
Jagriti Upadhyay, Stergios A Polyzos, Nikolaos Perakakis, Bindiya Thakkar, Stavroula A Paschou, Niki Katsiki, Patricia Underwood, Kyung-Hee Park, Jochen Seufert, Eun Seok Kang,[...]. Metabolism 2018
82



Pharmacologic Glycemic Management of Type 2 Diabetes in Adults.
Lorraine Lipscombe, Gillian Booth, Sonia Butalia, Kaberi Dasgupta, Dean T Eurich, Ronald Goldenberg, Nadia Khan, Lori MacCallum, Baiju R Shah, Scot Simpson. Can J Diabetes 2018
87

Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial.
Ting-Ting Yin, Yan Bi, Ping Li, Shan-Mei Shen, Xiao-Lu Xiong, Li-Jun Gao, Can Jiang, Yan Wang, Wen-Huan Feng, Da-Long Zhu. Diabetes Ther 2018
10

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms.
Manfredi Rizzo, Dragana Nikolic, Angelo Maria Patti, Carlo Mannina, Giuseppe Montalto, Brooke S McAdams, Ali A Rizvi, Francesco Cosentino. Biochim Biophys Acta Mol Basis Dis 2018
41


Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Inka Miñambres, Antonio Pérez. Diabetol Metab Syndr 2017
12






Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.
Kelvin Lingjet Tran, Young In Park, Shalin Pandya, Navin John Muliyil, Brandon David Jensen, Kovin Huynh, Quang T Nguyen. Am Health Drug Benefits 2017
47